2018.03.15
License Agreement Has Been Entered with Platelet Biogenesis, Inc.
License-Out
We executed a non-exclusive license agreement with Platelet Biogenesis, Inc. (Cambridge, U.S.A.) for the use of iPS cell-derived platelet products for human regenerative therapy, on the patents related to iPS cell technology that have been sublicensed to us by Kyoto University.